文献速递免疫规划传染病防控与疫情报告

在美國兩個州利用令牌化評估BNT162b2 XBB.1.5疫苗在免疫功能正常成人中的有效性

Effectiveness of BNT162b2 XBB.1.5 vaccine in immunocompetent adults using tokenization in two U.S. states.
PubMed 文献 · Vaccine · 2025-02-22

本研究為回顧性隊列研究,納入2023年9月25日至2024年3月31日期間加州和路易斯安那州18歲及以上免疫功能正常非孕成人共6,344,448人。隨訪中位6.3個月,4%接種BNT162b2 XBB.1.5疫苗。該疫苗對COVID-19相關住院和急診就診的疫苗有效性分別為36%(95%CI:18-50%)和45%(95%CI:34-54%)。先前配方無顯著殘餘保護。

要点

  • BNT162b2 XBB.1.5疫苗對COVID-19相關住院的有效性為36%(95%CI:18-50%)。
  • BNT162b2 XBB.1.5疫苗對COVID-19相關急診就診的有效性為45%(95%CI:34-54%)。
  • 先前配方未提供顯著殘餘保護。

核心结论

  • BNT162b2 XBB.1.5疫苗在2023-2024年秋冬季呼吸道病毒流行季為免疫功能正常成人提供了對COVID-19相關住院和急診就診的顯著額外保護。

研究设计与样本

  • 回顧性隊列研究,納入2023年9月25日至2024年3月31日期間加州和路易斯安那州18歲及以上、免疫功能正常、非懷孕、參加HealthVerity報告的健康保險計劃的居民,共6,344,448人。

主要发现

  • 隨訪中位6.3個月時,254,068人(4%)接種了BNT162b2 XBB.1.5疫苗。
  • COVID-19相關住院共2,346例,其中68例接種疫苗、2,278例未接種;急診就診共9,327例,其中135例接種疫苗、9,192例未接種。
  • 疫苗對COVID-19相關住院的有效性為36%(95%CI:18-50%),對急診就診的有效性為45%(95%CI:34-54%)。
  • 先前配方未提供顯著殘餘保護。

局限性

  • 原文未報告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data describing the effectiveness of COVID-19 vaccines during the 2023-2024 fall and winter viral respiratory season are lacking. We estimated BNT162b2 XBB.1.5 vaccine effectiveness (VE) against COVID-19-associated hospital admission and emergency department (ED) visits in two heterogenous U.S. States. METHODS: We conducted a retrospective cohort study among immunocompetent non-pregnant adults ≥18 years of age between September 25, 2023, and March 31, 2024 who were residents of California or Louisiana and enrolled in health insurance plans reporting to HealthVerity. Receipt of BNT162b2 XBB.1.5 vaccine was determined using State vaccine registry data (in addition to health insurance claims) and measured as a time-varying exposure. VE against COVID-19-associated hospital admission and ED visits was measured as 1- adjusted hazard ratio from Cox proportional hazards models. Models were adjusted for age, sex, State, insurance payor, presence of any condition(s) indicating CDC-defined high risk for severe COVID-19, wellness visit, influenza vaccination, outpatient visits, emergency department visits, and whether they had medically attended COVID-19 in the 91 to 365 days prior to index. RESULTS: Overall, 6,344,448 individuals met selection criteria. Median age was 40 years and 54% were female. By the end of follow-up (median 6.3 months), 254,068 (4%) had received a BNT162b2 XBB.1.5 vaccine; 2346 (of whom 68 received BNT162b2 XBB.1.5 vaccine and 2278 did not) and 9327 (of whom 135 received BNT162b2 XBB.1.5 vaccine and 9192 did not) experienced a COVID-19-associated hospital admission and ED visit, respectively. VE was 36% (95% confidence interval [CI]: 18-50%) and 45% (95% CI: 34-54%) against COVID-19-associated hospital admission and ED visits, respectively. Prior formulations offered no significant residual protection. DISCUSSION: BNT162b2 XBB.1.5 vaccine provided significant additional protection for immunocompetent adults against COVID-19-associated hospital admission and emergency department visits during the 2023-2024 fall and winter respiratory virus season. This study is registered on clinicaltrials.gov as NCT06199934.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Andersen KM, Allen KE, Nepal RM, et al. Effectiveness of BNT162b2 XBB.1.5 vaccine in immunocompetent adults using tokenization in two U.S. states. Vaccine. 2025. PMID: 39987879. doi:10.1016/j.vaccine.2025.126881

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。